0
Your cart

Your cart is empty

Browse All Departments
Price
  • R100 - R250 (8)
  • R250 - R500 (48)
  • R500+ (594)
  • -
Status
Format
Author / Contributor
Publisher

Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries

Empire Of Pain - The Secret History of the Sackler Dynasty (Paperback): Patrick Radden Keefe Empire Of Pain - The Secret History of the Sackler Dynasty (Paperback)
Patrick Radden Keefe
R380 R297 Discovery Miles 2 970 Save R83 (22%) Ships in 5 - 10 working days

The gripping and shocking story of three generations of the Sackler family and their roles in the stories of Valium and Oxycontin, by the prize-winning, bestselling author of Say Nothing.

The Sackler name adorns the walls of many storied institutions – Harvard; the Metropolitan Museum of Art; Oxford; the Louvre. They are one of the richest families in the world, known for their lavish donations in the arts and the sciences. The source of the family fortune was vague, however, until it emerged that the Sacklers were responsible for making and marketing Oxycontin, a blockbuster painkiller that was a catalyst for the opioid crisis-an international epidemic of drug addiction which has killed nearly half a million people.

In this masterpiece of narrative reporting and writing, Patrick Radden Keefe exhaustively documents the jaw-dropping and ferociously compelling reality. Empire of Pain is the story of a dynasty: a parable of 21st century greed.

Pharmacology In Clinical Practice - Application Made Easy For Nurses, Pharmacists And Allied Health Professionals (Paperback,... Pharmacology In Clinical Practice - Application Made Easy For Nurses, Pharmacists And Allied Health Professionals (Paperback, 3rd Edition)
Gustav Schellack
R532 R469 Discovery Miles 4 690 Save R63 (12%) Ships in 4 - 8 working days

Now in its third edition, Pharmacology in Clinical Practice has been updated to ensure it remains up-to-date and relevant.

Particular care has been taken to simplify and clarify difficult concepts by explaining the links between pharmacology and physiology by providing definitions of new concepts, and using plain language for ease of understanding. Fundamental concepts, such as pharmacodynamics and pharmacokinetics, are well covered in a matter that is accessible and clear. Individual chapters cover the various systems of the body.

Updates include:

  • A colour plate to illustrate the links between pharmacology and physiology
  • Additional information on side-effects, contra-indications and patient education for groups of drugs
  • A guide on how to access this information, to assist with exam preparation and nursing practice
  • An updated chapter on nursing management of drug preparations and treatment
  • An updated chapter on clinical applications
  • A chapter on the legal framework for dispensing and prescribing.
Death in Mud Lick - A Coal Country Fight Against the Drug Companies That Delivered the Opioid Epidemic (Paperback): Eric Eyre Death in Mud Lick - A Coal Country Fight Against the Drug Companies That Delivered the Opioid Epidemic (Paperback)
Eric Eyre
R467 R386 Discovery Miles 3 860 Save R81 (17%) Ships in 10 - 15 working days
The Hard Sell - Crime and Punishment at an Opioid Startup (Paperback): Evan Hughes The Hard Sell - Crime and Punishment at an Opioid Startup (Paperback)
Evan Hughes
R299 R234 Discovery Miles 2 340 Save R65 (22%) Ships in 5 - 10 working days

Soon to be the major motion picture Pain Hustlers starring Emily Blunt and Chris Evans streaming on Netflix ‘A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market. Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids. With colourful characters and true suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .

EU Competition Law and Pharmaceuticals (Hardcover): Wolf Sauter, Marcel Canoy, Jotte Mulder EU Competition Law and Pharmaceuticals (Hardcover)
Wolf Sauter, Marcel Canoy, Jotte Mulder
R3,443 Discovery Miles 34 430 Ships in 12 - 17 working days

This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control. The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels - in the context of current issues and future trends, including those related to COVID-19 - and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed. Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.

The Hard Sell - Crime and Punishment at an Opioid Startup (Paperback): Evan Hughes The Hard Sell - Crime and Punishment at an Opioid Startup (Paperback)
Evan Hughes
R380 R297 Discovery Miles 2 970 Save R83 (22%) Ships in 5 - 10 working days

Soon to be the major motion picture Pain Hustlers starring Emily Blunt and Chris Evans streaming on Netflix ‘A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market. Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids. With colourful characters and true suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .

The Commercialization of Pharmaceutical Patents in China (Hardcover): James Hou The Commercialization of Pharmaceutical Patents in China (Hardcover)
James Hou
R2,849 Discovery Miles 28 490 Ships in 12 - 17 working days

Presenting detailed analysis of the industrialization and commercialization of pharmaceutical patents in China, this timely book explores a range of related topics including a comparison of the ideal and existing state of the pharmaceutical market and patent industrialization. It argues that the core purpose of the industrialization of pharmaceutical patents is to promote the development of the local pharmaceutical industry whist also protecting society's right to safe and effective medication. Chapters examine the special application issues of patent law in relation to the field of pharmaceuticals, compare the Chinese and American legal systems and their approach to pharmaceutical patents, and provide in depth political and legal analysis of the industry. James Hou suggests methods by which the Chinese legal system can seek to improve its governance of pharmaceutical patents and balance the conflicts of interest arising between new drug developers, established drug manufacturers and the end users. Featuring comprehensive coverage of patents in the Chinese pharmaceutical industry, this book will be a key resource for scholars and students of commercial, pharmaceutical and intellectual property law, whilst also being of interest to industry talents discovering the potential of their own innovations.

Empire of Pain - The Secret History of the Sackler Dynasty (Paperback): Patrick Radden Keefe Empire of Pain - The Secret History of the Sackler Dynasty (Paperback)
Patrick Radden Keefe
R280 R219 Discovery Miles 2 190 Save R61 (22%) Ships in 5 - 10 working days

The inspiration behind the Netflix tv series Painkillers, starring Uzo Aduba and Matthew Broderick THE SUNDAY TIMES BESTSELLER Now on BBC Radio 4 'Book of the Week' Winner of the 2021 Baillie Gifford Prize for Non-Fiction Shortlisted for the 2021 Financial Times/McKinsey Business Book of the Year Award One of Barack Obama's Favorite Books of 2021 Shortlisted for the Crime Writers' Association Gold Dagger for Non-Fiction The gripping and shocking story of three generations of the Sackler family and their roles in the stories of Valium, OxyContin and the opioid crisis. 'One of those authors I will always read, no matter what the subject matter, which is why I gobbled up Empire of Pain . . . a masterclass in compelling narrative nonfiction.' - Elizabeth Day, The Guardian '30 Best Summer Reads' 'You feel almost guilty for enjoying it so much' - The Times The Sackler name adorns the walls of many storied institutions - Harvard; the Metropolitan Museum of Art; Oxford; the Louvre. They are one of the richest families in the world, known for their lavish donations in the arts and the sciences. The source of the family fortune was vague, however, until it emerged that the Sacklers were responsible for making and marketing Oxycontin, a blockbuster painkiller that was a catalyst for the opioid crisis - an international epidemic of drug addiction which has killed nearly half a million people. In this masterpiece of narrative reporting and writing, award-winning journalist and host of the Wind of Change podcast Patrick Radden Keefe exhaustively documents the jaw-dropping and ferociously compelling reality. Empire of Pain is the story of a dynasty: a parable of twenty-first-century greed.

Regulation of Synthetic Biology - BioBricks, Biopunks and Bioentrepreneurs (Hardcover): Alison McLennan Regulation of Synthetic Biology - BioBricks, Biopunks and Bioentrepreneurs (Hardcover)
Alison McLennan
R4,009 Discovery Miles 40 090 Ships in 12 - 17 working days

This book explores the interplay between regulation and emerging technologies in the context of synthetic biology, a developing field that promises great benefits, and has already yielded fuels and medicines made with designer micro-organisms. For all its promise, however, it also poses various risks. Investigating the distinctiveness of synthetic biology and the regulatory issues that arise, Alison McLennan questions whether synthetic biology can be regulated within existing structures or whether new mechanisms are needed. Adopting an interdisciplinary approach, McLennan draws on diverse areas of law, the science of synthetic biology and the history and sociology of science. She concludes that synthetic biology presents novel regulatory challenges relating to environmental risk, biosafety, biosecurity and intellectual property. These challenges arise from the uniqueness of the science, the nature of its communities of scientists (including citizen scientists or 'biobunks') and the uncertainty surrounding possible hazards. Some scientists see intellectual property protection as a way to push innovation forward (bioentrepreneurs), while others openly share synthetic biology tools such as BioBricks. By understanding the range of regulatory challenges, the book make a case for enhanced regulation that protects us from synthetic biology's risks, whilst capturing its potential to improve our world. Regulation of Synthetic Biology will be essential reading for academics and students in the social sciences and law, as well as for scientists working in synthetic biology, and policymakers in innovation, science and the regulation of these fields.

Over the Counter Medicines (Paperback): Alan Maynard, Gerald Richardson Over the Counter Medicines (Paperback)
Alan Maynard, Gerald Richardson
R272 Discovery Miles 2 720 Ships in 12 - 17 working days
Innovation in the Pharmaceutical Industry - The Process of Drug Discovery and Development (Hardcover): Takuji Hara Innovation in the Pharmaceutical Industry - The Process of Drug Discovery and Development (Hardcover)
Takuji Hara
R3,300 Discovery Miles 33 000 Ships in 12 - 17 working days

Innovation in the Pharmaceutical Industry traces the discovery and development of drugs in Japan and the UK both historically and sociologically. It includes sixteen case studies of major pharmaceutical developments in the twentieth century, encompassing, amongst others, beta-blockers, beta-stimulants, inhaled steroids and histamine H2-antagonists. The book illustrates that the four stages of drug development - namely compound, application, organisational authorisation and market - are interactively shaped by heterogeneous actors and institutions. The book also identifies three different types of pharmaceutical development - paradigmatic innovation, application innovation and modification-based innovation, all with distinguishable features in the drug development process. Finally, several historical, structural and cultural factors influencing the shaping of medicines are revealed by the comparison between British and Japanese drug innovation. Addressing a number of practical implications for the promotion of the pharmaceutical industry, this book will be of enormous interest to students, researchers and academics specialising in science and technology, and the management of technology and innovation. Practitioners, managers, and policy planners within the pharmaceutical industry will also deem this book invaluable.

For Blood and Money - Billionaires, Biotech, and the Quest for a Blockbuster Drug (Hardcover): Nathan Vardi For Blood and Money - Billionaires, Biotech, and the Quest for a Blockbuster Drug (Hardcover)
Nathan Vardi
R789 R637 Discovery Miles 6 370 Save R152 (19%) Ships in 10 - 15 working days

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team-denied their share of the profits-went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time. In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks-and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big. What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi's narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine.

Forecasting for the Pharmaceutical Industry - Models for New Product and In-Market Forecasting and How to Use Them (Hardcover,... Forecasting for the Pharmaceutical Industry - Models for New Product and In-Market Forecasting and How to Use Them (Hardcover, 2nd edition)
Arthur G. Cook
R3,849 Discovery Miles 38 490 Ships in 9 - 15 working days

Forecasting for the Pharmaceutical Industry is a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making. In virtually every decision, a pharmaceutical executive considers some type of forecast. This process of predicting the future is crucial to many aspects of the company - from next month's production schedule, to market estimates for drugs in the next decade. The pharmaceutical forecaster needs to strike a delicate balance between over-engineering the forecast - including rafts of data and complex 'black box' equations that few stakeholders understand and even fewer buy into - and an overly simplistic approach that relies too heavily on anecdotal information and opinion. Arthur G. Cook's highly pragmatic guide explains the basis of a successful balanced forecast for products in development as well as currently marketed products. The author explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches. The text is liberally illustrated with tables, diagrams and examples. The final extended case study provides the reader with an opportunity to test out their knowledge. The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars.

Advanced Nanoformulations - Theranostic Nanosystems, Volume 3 (Paperback): Md Saquib Hasnain, Amit Kumar Nayak, Tejraj M.... Advanced Nanoformulations - Theranostic Nanosystems, Volume 3 (Paperback)
Md Saquib Hasnain, Amit Kumar Nayak, Tejraj M. Aminabhavi
R4,108 Discovery Miles 41 080 Ships in 12 - 17 working days

Advanced Nanoformulations: Theranostic Nanosystems, Volume Three examines the applications of nanotherapeutic systems and nanodiagnostics in relation to polymeric nanosystems. In the last decade, numerous biopolymers have been utilized to prepare polymeric nanosystems for therapeutic applications. These biopolymers include polylactic acid, polylactide-co-glycolide, polycaprolactone, acrylic polymers, cellulose and cellulose derivatives, alginates, chitosan, gellan gum, gelatin, albumin, chontroitin sulfate, hyaluronic acid, guar gum, gum Arabic, gum tragacanth, xanthan gum, and starches. Besides these biopolymers, grafted polymers are also being used as advanced polymeric materials to prepare many theranostic nanocarriers and nanoformulations. This book explores the array of polymeric nanosystems to understand therapeutic potentials. It will be useful to pharmaceutical scientists, including industrial pharmacists and analytical scientists, health care professionals, and regulatory scientists actively involved in the pharmaceutical product and process development of tailor-made polysaccharides in drug delivery applications.

Tamoxifen Tales - Suggestions for Scientific Survival (Hardcover): V.Craig Jordan Tamoxifen Tales - Suggestions for Scientific Survival (Hardcover)
V.Craig Jordan
R2,142 Discovery Miles 21 420 Ships in 12 - 17 working days

Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting lessons learned that are applicable to the next generation of scientists. This book provides a manual on the successful mentoring of young scientists, including stories describing how training experience shaped careers to become leaders in academia and the pharmaceutical industry. The book documents Professor V. Craig Jordan's 50-year career in medical sciences that led to the discovery and development of Selective Estrogen Receptor Modulators (SERMs), which became the standard of women's healthcare around the world. Additionally, it illustrates the versatility of a scientist with a commitment to serving societies. This important resource will be a useful and interesting book for established medical scientists, research mentors and advanced students wanting to chart a successful and impactful research career.

Strategic Pharmaceutical Marketing Management in Growth Markets (Paperback): Mithun Nandy Strategic Pharmaceutical Marketing Management in Growth Markets (Paperback)
Mithun Nandy
R1,097 Discovery Miles 10 970 Ships in 9 - 15 working days

India is the largest provider of generic drugs globally. The Indian pharmaceutical sector supplies over 50 per cent of the global demand for various vaccines, and as a result, holds an important position in the global pharmaceutical sector. This book is a comprehensive study of pharmaceutical marketing management in the Indian context and similar growth markets. The book introduces the fast-paced and multi-faceted discipline of pharmaceutical marketing management through an in-depth discussion on the genesis and evolution of its marketing concept. Combining theory and practice, it offers a strategic approach to pharmaceutical marketing from an organisational and business perspective and explicates the practical applications of it. Richly supported by case studies, the book brings together fresh perspectives and approaches equally useful for students and professionals. This book will be of interest to academicians, advanced students, and practitioners of pharmaceutical marketing and pharmaceutical management. It will also be beneficial to those interested in business strategy, decision making, and international marketing.

Powering Social Enterprise with Profit and Purpose - The Tandem Hybrid (Paperback): Scott Boyer, Jeremy Gudauskas, Mike Hamel Powering Social Enterprise with Profit and Purpose - The Tandem Hybrid (Paperback)
Scott Boyer, Jeremy Gudauskas, Mike Hamel
R947 Discovery Miles 9 470 Ships in 9 - 15 working days

Trail-blazing social entrepreneurs are tackling the world's most pressing problems that government, business, or charity have failed to solve. They are creating businesses with a primary mission of social change. Scott Boyer is one such social entrepreneur. This 28-year veteran of Big Pharma left a six-figure salary to start OWP Pharmaceuticals and the ROW Foundation. This commercial business and non-profit organization exist in a symbiotic relationship we call a "tandem hybrid social enterprise." This model combines a multimillion dollar business with a foundation that's on track to become the largest funder of projects serving people with epilepsy and associated psychiatric disorders in the world. The tandem hybrid incorporates the principles learned by Scott and others for building a truly unique social enterprise from the ground up; one that is: Driven by a compelling social mission Financed by commercial success Structured to retain control Scalable and sustainable for the long haul Powering Social Enterprises With Profit And Purpose offers a detailed blueprint that has proven commercially and philanthropically successful and that can be replicated in most business sectors.

Smart Polymeric Nano-Constructs in Drug Delivery - Concept, Design and Therapeutic Applications (Paperback): Suresh P. Vyas,... Smart Polymeric Nano-Constructs in Drug Delivery - Concept, Design and Therapeutic Applications (Paperback)
Suresh P. Vyas, Udita Agrawal, Rajeev Sharma
R4,056 Discovery Miles 40 560 Ships in 12 - 17 working days

Smart Polymeric Nano-Constructs in Drug Delivery: Concept, Design and Therapeutic Applications provides a thorough discussion of the most state of the art material and polymer exploitations for the delivery of bioactive(s) as well as their current and clinical status. The book enables researchers to prepare a variety of smart drug delivery systems to investigate their properties as well as to discover their uses and applications. The novelty of this approach addresses an existing need of exhaustively understanding the potential of the materials including polymeric drug delivery systems that are smartly designed to deliver bioactive(s) into the body at targeted sites without showing side effects. The book is helpful for those in the health sector, specifically those developing nanomedicine using smart material-based nano-delivery systems. Polymers have unique co-operative properties that are not found with low-molecular-weight compounds along with their appealing physical and chemical properties, constituting the root of their success in drug delivery. Smart Polymeric Nano-Constructs in Drug Delivery: Concept, Design and Therapeutic Applications discusses smart and stimuli responsive polymers applicable in drug delivery, followed detailed information about various concepts and designing of polymeric novel drug delivery systems for treatment of various type of diseases, also discussing patents related to the field. The book helps readers to design and develop novel drug delivery systems based on smart materials for the effective delivery of bioactive that take advantage of recent advances in smart polymer-based strategies. It is useful to those in pharmaceutical sciences and related fields in developing new drug delivery systems.

Drug Delivery Systems for Metabolic Disorders (Paperback): Harish Dureja, Narasimha Murthy, Peter Wich, Kamal Dua Drug Delivery Systems for Metabolic Disorders (Paperback)
Harish Dureja, Narasimha Murthy, Peter Wich, Kamal Dua
R4,056 Discovery Miles 40 560 Ships in 12 - 17 working days

Drug Delivery Systems for Metabolic Disorders presents the most recent developments on the targeted delivery of drugs to deal with metabolic disorders in a safe, compliant and continuous way. The book covers recent developments in advanced drug delivery systems in various metabolic disorders, including disturbances in protein, lipid, carbohydrate and hormone metabolism and lysosomal and mitochondrial disorders. It provides a brief introduction to metabolic disorders, along with a focus on the current landscape and trends in understanding disease pathology using different in vitro and in vivo models required for clinical applications and developments of new therapeutics. Each subsequent chapter covers drug delivery systems dedicated to metabolic diseases caused by disturbances in protein, lipid, carbohydrate and hormone metabolism. Then, it moves on to cover lysosomal storage disorders and applications of phytopharmaceuticals in this context. This is the perfect reference for researchers in pharmaceutical science who are interested in developing new treatments for metabolic diseases.

Targeted Nanomedicine for Breast Cancer Therapy (Paperback): Shivani Rai Paliwal, Rishi Paliwal Targeted Nanomedicine for Breast Cancer Therapy (Paperback)
Shivani Rai Paliwal, Rishi Paliwal
R4,645 Discovery Miles 46 450 Ships in 12 - 17 working days

Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry. Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available.

Bad Pharma - How Medicine is Broken, and How We Can Fix it (Paperback): Ben Goldacre Bad Pharma - How Medicine is Broken, and How We Can Fix it (Paperback)
Ben Goldacre 1
R367 R303 Discovery Miles 3 030 Save R64 (17%) Ships in 12 - 17 working days

'Bad Science' hilariously exposed the tricks that quacks and journalists use to distort science, becoming a 400,000 copy bestseller. Now Ben Goldacre puts the $600bn global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess. Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply buried. All of this is perfectly legal. In fact, even government regulators withhold vitally important data from the people who need it most. Doctors and patient groups have stood by too, and failed to protect us. Instead, they take money and favours, in a world so fractured that medics and nurses are now educated by the drugs industry. The result: patients are harmed in huge numbers. Ben Goldacre is Britain's finest writer on the science behind medicine, and 'Bad Pharma' is the book that finally prompted Parliament to ask why all trial results aren't made publicly available - this edition has been updated with the latest news from the select committee hearings. Let the witty and indefatigable Goldacre show you how medicine went wrong, and what you can do to mend it.

Cancer, Radiation Therapy, and the Market (Hardcover): Barbara Bridgman Perkins Cancer, Radiation Therapy, and the Market (Hardcover)
Barbara Bridgman Perkins
R3,912 Discovery Miles 39 120 Ships in 12 - 17 working days

Appraising cancer as a major medical market in the 2010s, Wall Street investors placed their bets on single-technology treatment facilities costing $100-$300 million each. Critics inside medicine called the widely-publicized proton-center boom "crazy medicine and unsustainable public policy." There was no valid evidence, they claimed, that proton beams were more effective than less costly alternatives. But developers expected insurance to cover their centers' staggeringly high costs and debts. Was speculation like this new to health care? Cancer, Radiation Therapy, and the Market shows how the radiation therapy specialty in the United States (later called radiation oncology) coevolved with its device industry throughout the twentieth-century. Academic engineers and physicians acquired financing to develop increasingly powerful radiation devices, initiated companies to manufacture the devices competitively, and designed hospital and freestanding procedure units to utilize them. In the process, they incorporated market strategies into medical organization and practice. Although palliative benefits and striking tumor reductions fueled hopes of curing cancer, scientific research all too often found serious patient harm and disappointing beneficial impact on cancer survival. This thoroughly documented and provocative inquiry concludes that public health policy needs to re-evaluate market-driven high-tech medicine and build evidence-based health care systems.

Unnecessary Expense - An Antidote for the Billion Dollar Drug Problem (Hardcover): Charles Theuer, Bonne Adams, Mark Wiggins,... Unnecessary Expense - An Antidote for the Billion Dollar Drug Problem (Hardcover)
Charles Theuer, Bonne Adams, Mark Wiggins, Scott Brown
R798 R665 Discovery Miles 6 650 Save R133 (17%) Ships in 10 - 15 working days
Medicines in China's National Health Insurance System (Hardcover): China Development Research Foundation Medicines in China's National Health Insurance System (Hardcover)
China Development Research Foundation
R4,600 Discovery Miles 46 000 Ships in 9 - 15 working days

This book presents the findings of systematic research into the healthcare medicine management policies of China. In-depth comprehensive research has been carried out, targeting multiple issues of particular importance in healthcare medicine management, such as the purchasing, pricing, payment, usage, and the function of commercial healthcare insurance in medical payment. The book goes on to put forward policy advice regarding the aforementioned issues.

Herbal Bioactive-Based Drug Delivery Systems - Challenges and Opportunities (Paperback): Inderbir Singh Bakshi, Rajni Bala,... Herbal Bioactive-Based Drug Delivery Systems - Challenges and Opportunities (Paperback)
Inderbir Singh Bakshi, Rajni Bala, Reecha Madaan, Rakesh K. Sindhu
R4,100 Discovery Miles 41 000 Ships in 12 - 17 working days

Herbal Bioactive-Based Drug Delivery Systems: Challenges and Opportunities provides a wide-ranging, in-depth resource for herbal bioactives, including detailed discussion of standardization and regulations. The book first explores specific drug delivery systems such as gastrointestinal, ocular, pulmonary, transdermal, and vaginal and rectal. It then discusses novel applications for nano, cosmetics, nutraceuticals, wound healing and cancer treatment. Finally, there is a section focusing on standardization and regulation which includes an enhancement of properties. This book is an essential resource for pharmacologists, pharmaceutical scientists, material scientists, botanists, and all those interested in natural products and drug delivery systems developments.

Free Delivery
Pinterest Twitter Facebook Google+
You may like...
Licensing, Selling and Finance in the…
Martin Austin Hardcover R3,914 Discovery Miles 39 140
Project Management for the…
Laura Brown, Tony Grundy Hardcover R4,079 Discovery Miles 40 790
The Future of Pharmaceutical Product…
Rakesh Kumar Tekade Hardcover R4,236 Discovery Miles 42 360
Particulate Drying - Techniques and…
Sachin Vinayak Jangam, Chung-Lim Law, … Hardcover R3,474 Discovery Miles 34 740
Pharmaceutical Product Development…
Vandana B Patravale, John I Disouza, … Paperback R1,419 Discovery Miles 14 190
Advanced Manufacturing Operations…
Sam A. Hout Hardcover R3,174 Discovery Miles 31 740
Pharmaceutical Innovation, Competition…
Josef Drexl, Nari Lee Hardcover R3,797 Discovery Miles 37 970
Herbal Medicine - Chaos in the…
Virginia M. Tyler, Rowena Richter Paperback R1,175 Discovery Miles 11 750
Pharmaceutical Economics
William S. Comanor, Stuart O. Schweitzer Hardcover R10,200 Discovery Miles 102 000
Citrus - The Genus Citrus
Giovanni Dugo, Angelo Di Giacomo Hardcover R5,445 Discovery Miles 54 450

 

Partners